Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review

May 23, 2025Current obesity reports

Bariatric Surgery and Diabetes Medications for Treating Obstructive Sleep Apnea

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Bariatric surgery typically results in faster and more sustained weight loss compared to pharmacological interventions targeting GLP-1 and GIP receptors.

Obstructive sleep apnea (OSA) is linked to obesity, which contributes to the condition's severity.
Limited direct comparisons exist between bariatric surgery and pharmacotherapy for OSA treatment.
Observational studies indicate that bariatric surgery may lead to better initial improvements in OSA symptoms.
Pharmacological options may be suitable for patients who are unable to undergo surgical procedures.
Randomized trials are needed to better define treatment strategies for OSA management.
A multidisciplinary approach is important for achieving long-term success in treating obesity-related OSA.

AI simplified

PURPOSE OF REVIEW: This review evaluates the comparative efficacy of bariatric surgery and pharmacological interventions targeting Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. Recent advancements, including the FDA approval of Tirzepatide (Zepbound) for OSA, are critically analysed alongside existing literature, offering insights into physiological mechanisms, long-term outcomes, and patient selection criteria.

RECENT FINDINGS: OSA is a chronic condition characterized by repetitive upper airway collapse during sleep, resulting in intermittent hypoxia and sleep fragmentation. With obesity being a primary risk factor, weight management has emerged as a key intervention in OSA treatment. Direct comparisons of bariatric surgery and GLP-1/GIP receptor agonists in treating OSA are limited due to a lack of randomised controlled trials. Observational studies suggest that bariatric surgery typically results in faster and more sustained weight loss, leading to better initial OSA improvement. In contrast, pharmacotherapy offers a non-invasive option for patients who cannot undergo surgery. Randomized trials comparing these treatment modalities are essential to refine treatment algorithms and enhance patient care. A multidisciplinary, patient-centered approach is crucial for ensuring long-term success and improving the quality of life for individuals with obesity-related OSA.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief